DATA GRAPHICS | Data Byte
Biotech’s negative catalyst run
A string of poor catalyst outcomes contributed to negative sentiment toward biotech in 1Q22
April 11, 2022 11:01 PM UTC
One of the major contributors to the negative outlook on the biotech markets in the first quarter was a run of disappointing catalyst outcomes.
An analysis of a selection of 88 late-stage clinical and regulatory events showed that 57 (65%) had a negative outcome, with clinical failures or holds accounting for 68% of the negative outcomes...